Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Michael (Luhua) Wang, MD, Fredrick Hagemeister, MD, Jason R. Westin, MD, Luis Fayad, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Wendy Chen, Liang Zhang, MD PhD, Maria Badillo, BS, Maria DeLa Rosa, Alicia Addison, Larry W. Kwak, MD PhD, Jorge E. Romaguera, MD

Blood (2014) 124 (21): 627.

https://doi.org/10.1182/blood.V124.21.627.627

Published: 2014

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Felipe Samaniego, MD, Jillian F Wise, BS, Luis Fayad, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Vijairam Selvaraj, MD, David M. Goldenberg, ScD, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2011) 118 (21): 1796.

https://doi.org/10.1182/blood.V118.21.1796.1796

Published: 2011

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD

Blood (2010) 116 (21): 3964.

https://doi.org/10.1182/blood.V116.21.3964.3964

Published: 2010

Journal Articles

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Nicolas Batty, MD, Elham Ghonimi, MD, Lei Feng, PhD, Anas Younes, MD, Rodriguez Alma, MD, Elizabeth Wager, MD, Fernando Martinez, MD, MPH, Michael Wang, MD, Peter McLaughlin, MD, Nathan Fowler, MD, Fredrick Hagemeister, MD

Blood (2010) 116 (21): 3357.

https://doi.org/10.1182/blood.V116.21.3357.3357

Published: 2010

Journal Articles

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Deborah A. Thomas, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Rebecca Garris, BA, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 1781.

https://doi.org/10.1182/blood.V116.21.1781.1781

Published: 2010

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Martin Korbling, MD, Chitra Hosing, MD, Luis Fayad, MD, Ming S. Lee, MD, Felipe Samaniego, MD, Barry I. Samuels, MD, Daniel Couriel, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Richard E. Champlin, MD

Blood (2007) 110 (11): 485.

https://doi.org/10.1182/blood.V110.11.485.485

Published: 2007

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

Journal Articles

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Maria Alma Rodriguez, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Larry Kwak, MD, Ph.D., Luis Fayad, MD, Xuelin Huang, Ph.D, Jean Bernard Durand, MD

Blood (2007) 110 (11): 4468.

https://doi.org/10.1182/blood.V110.11.4468.4468

Published: 2007

Journal Articles

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

Barbara Pro, MD, Rodolfo F. Nunez, MD, Jorge Romaguera, MD, Maria A. Rodriguez, MD, Fredrick Hagemeister, MD, Luis Fayad, MD

Blood (2006) 108 (11): 2404.

https://doi.org/10.1182/blood.V108.11.2404.2404

Published: 2006

Journal Articles

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Jorge Enrique Romaguera, MD, Luis E. Fayad, MD, Michael Wang, MD, Fernando Cabanillas, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Alma Rodriguez, MD, Anas Younes, MD, Sattva Neelapu, MD, Andre H. Goy, MD, Virginia Beasley, Larry Kwak, MD, PhD

Blood (2005) 106 (11): 2446.

https://doi.org/10.1182/blood.V106.11.2446.2446

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Peter McLaughlin, MD, Luis Fayad, MD, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Anas Younes, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Pamela L. Walker, RN, Maria A. Rodriguez, MD, Larry Kwak, MD, PhD, Barbara Pro, MD

Blood (2005) 106 (11): 3349.

https://doi.org/10.1182/blood.V106.11.3349.3349

Published: 2005

Journal Articles

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Maria Rodriguez, MD, Andre Goy, MD, Jorge Romaguera, MD, Pamela L. Walker, RN, Anas Younes, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2005) 106 (11): 3350.

https://doi.org/10.1182/blood.V106.11.3350.3350

Published: 2005

Journal Articles

Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Susan O’Brien, MD, Carlos Bueso-Ramos, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Francis Giles, MD, Srdan Verstovsek, MD, PhD, William Wierda, MD, PhD, Sherry Pierce, RN, Jiaquin Shan, Mark Brandt, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Michael J. Keating, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 149.

https://doi.org/10.1182/blood.V106.11.149.149

Published: 2005

Journal Articles

Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL).

Luis Fayad, MD, Barbara Pro, MD, Qi Liu, MD, PhD, Mark Hess, Fredrick Hagemeister, MD, Jorge Romaguera, MD, Felipe Samaniego, MD, Fernando Cabanillas, MD, Alma Rodriguez, MD, Anas Younes, MD, Michael Wang, MD, Peter McLaughlin, MD

Blood (2005) 106 (11): 933.

https://doi.org/10.1182/blood.V106.11.933.933

Published: 2005

Journal Articles

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, Charles Koller, MD, BA, Fredrick Hagemeister, MD, BA, Luis Fayad, MD, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 976.

https://doi.org/10.1182/blood.V106.11.976.976

Published: 2005

Journal Articles

Phase II Study of Sphingosomal Vincristine in CHOP+/ − Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.

Maria Alma Rodriguez, MD, Nam H. Dang, MD, PhD, Luis Fayad, MD, Andre Goy, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Anas Younes, MD, Fernando Cabanillas, MD

Blood (2005) 106 (11): 943.

https://doi.org/10.1182/blood.V106.11.943.943

Published: 2005

NARROW

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).

Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL).

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Phase II Study of Sphingosomal Vincristine in CHOP+/ − Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only